Want to join the conversation?
$AMGN said Phase 3 GLAGOV trial evaluating the effect of Repatha (evolocumab) on coronary artery disease (CAD) or cardiovascular disease met its primary and secondary endpoints. The detailed results will be presented during upcoming American Heart Association (AHA) Scientific Sessions on Nov. 15, 2016.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.